MetLife Investment Management LLC Acquires 2,428 Shares of Repligen Co. (NASDAQ:RGEN)

MetLife Investment Management LLC raised its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 8.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,774 shares of the biotechnology company's stock after buying an additional 2,428 shares during the period. MetLife Investment Management LLC owned about 0.05% of Repligen worth $4,286,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Signaturefd LLC lifted its position in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new position in shares of Repligen in the fourth quarter valued at approximately $29,000. UMB Bank n.a. boosted its position in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after buying an additional 110 shares during the last quarter. Global Retirement Partners LLC grew its holdings in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after buying an additional 129 shares in the last quarter. Finally, Pilgrim Partners Asia Pte Ltd purchased a new stake in Repligen in the 4th quarter valued at $55,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Trading Up 2.7 %

Shares of RGEN opened at $145.23 on Friday. The firm has a market cap of $8.15 billion, a P/E ratio of -284.76, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. Repligen Co. has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The business has a 50-day moving average of $139.81 and a 200 day moving average of $145.73.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, research analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

Analyst Ratings Changes

RGEN has been the subject of several recent analyst reports. Evercore ISI began coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. Canaccord Genuity Group cut their target price on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research note on Wednesday, April 16th. JPMorgan Chase & Co. increased their price target on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Finally, TD Cowen began coverage on Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $176.82.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax acquired 250 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.